![]() Based on the Society of Thoracic Surgeons predicted risk of mortality, the arithmetic risk for surgery in the study cohort was 11% ± 9% (1% to 62%) and 20 (6%) patients were in cardiogenic shock. The study group consisted of all 324 patients who received the new generation of balloon-expandable prostheses (SAPIEN XT Edwards Lifesciences, LLC, Irvine, CA). Apart from data from very limited initial experience, predictors of leakage in large cohorts treated with new types of TAVI prostheses are still lacking.įrom April 2008 to August 2013, 730 patients underwent transapical TAVI at our institution. In line with our institutional strategy, we do not accept paravalvular leakage after transcatheter aortic valve implantation (TAVI). In contrast to PPM after SAVR, PPM after TAVI may not impair late survival. Overall, moderate, and severe PPM prevalence after TAVI was 35%, 27%, and 8%, respectively, which may be less than that after SAVR. The third meta-analyses of five studies, including 2,654 patients, found no statistically significant differences in late mortality between patients with severe PPM and patients without PPM ( p = 0.44) and between patients with overall PPM and patients without PPM ( p = 0.97). ![]() The second meta-analyses of six studies, including 745 patients, found statistically significant reductions in moderate ( p = 0.03), severe ( p = 0.0003), and overall ( p = 0.02) PPM prevalence after TAVI relative to SAVR. The first meta-analyses found moderate PPM prevalence of 26.7%, severe PPM prevalence of 8.0%, and overall PPM prevalence of 35.1%. We identified 21 eligible studies that included data on a total of 4,000 patients undergoing TAVI. We performed three quantitative meta-analyses about (1) PPM prevalence after TAVI, (2) PPM prevalence after TAVI versus surgical aortic valve replacement (SAVR), and (3) late all-cause mortality after TAVI in patients with PPM versus patients without PPM. Studies considered for inclusion met the following criteria: the study population included patients undergoing TAVI and outcomes included at least post-procedural PPM prevalence. To identify all studies that investigated PPM in TAVI, MEDLINE and EMBASE were searched through August 2015. We reviewed currently available studies that investigated prosthesis–patient mismatch (PPM) in transcatheter aortic valve implantation (TAVI) with a systematic literature search and meta-analytic estimates. The result is superior to that in TAVI candidates treated with surgical valve replacement. In congruence with recently reported results from an international registry of 120 patients from 20 centers, a half-year survival rate close to 90% may be achieved even in elderly and polymorbid patients. ![]() ![]() Performing a TAVI with the new 29-mm balloon-expandable prosthesis in our cohort of 78 patients showed good initial results in terms of clinical outcome. In the study group, there were two (2.6%) conversions to surgical aortic valve replacement after valve deployment because of annular Clinical Outcome According to the Valve Academic Research Consortium, the device success rate (Table 2) was 96.2% for the study group and 97.6% for the control group ( p = 0.676). The deployment of the 29-mm prosthesis (study group) and 26-mm prosthesis (control group) at the desired position in the DLZ was performed in all patients. The control group consisted Procedural Success The observation period was closed when the prosthesis became available for transfemoral access at our institution. The study cohort represents all 78 consecutive patients who underwent transapical TAVI at our institution with a new 29-mm balloon-expandable prosthesis (SAPIEN XT and ASCENDRA-I, Edwards Lifesciences) between April 2011 and July 2012. This was a retrospective, observational, single-center cohort study of prospectively and retrospectively collected data. Section snippets Patients and Study Design
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |